Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hisun Pharma Diversifies into Animal Health with New Partnership

publication date: Mar 16, 2012
Zhejiang Hisun Pharma signed an agreement with Piedmont Pharmaceuticals of the US to jointly develop products for the pet segment of the animal health market in China. Over the past few years, Hisun has proved itself to be a prolific dealmaker. Last month, it formed a $545 million JV with Pfizer to develop generic drugs. Hisun said the latest partnership will help it develop its new animal health business. More details....

Stock Symbols: (SHE: 600267) (NYSE: PFE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital